核心观点 - 公司被选入Jim Cramer的幻想投资组合 股价年初至今上涨约23% 表现强劲[1] - 核心制药业务增长强劲 肿瘤业务表现优异 医疗器械业务实力突出[1] - 滑石粉诉讼问题仍然存在但已不再是焦点问题[1] 业务概况 - 公司从事制药、医疗器械和视力保健产品的开发与销售[2] - 解决方案包括治疗疗法、手术技术和眼部健康解决方案[2] 市场表现 - 股价达到约180美元水平 在医疗保健板块普遍疲软背景下表现突出[1] - 持续发布良好财务数据 整体业务质量获得市场认可[1]

Key TakeawaysNew Zealand's annual net immigration surged to 13,066 in July, indicating robust population growth and potential economic expansion.Former President Trump signed a memo requiring pharmaceutical advertisements to disclose all risks, a move poised to significantly impact the drug industry's marketing strategies.The immigration increase could bolster New Zealand's labor market and consumer demand, while the pharma ad mandate is expected to increase compliance costs and potentially reduce advertisi ...

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative to surgically remove the organ. ...

Accessibility StatementSkip Navigation First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduction Potential practice-changing treatment for certain patients with BCG-unresponsive non-muscle invasive bladder cancer who have limited options before possible bladder removal RARITAN, N.J., Sept. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. ...

CHINA - 2025/09/04: In this photo illustration, Johnson & Johnson's logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance grounded in durable business fundamentals, or is it a temporary market anomaly? The evid ...

Sep 8, 2025 6:17 PM Eastern Daylight Time "We are pleased to welcome John to our Company's Board of Directors,†said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to drive innovation will be an incredible asset to Johnson & Johnson as we continue to deliver the next generation of health ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available app. ...

Along with Materials, the Health Care sector bounced back in August . Still, the space is down by more than 12% from a year ago, easily the worst-performing of the 11 S&P 500 groupings. There are green shoots, however.Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrative to finan ...

Johnson & Johnson (NYSE: JNJ ) (NEOE: JNJ:CA ) is an American healthcare heavyweight with a major focus on pharma and medical devices. The company used to sell consumer health and skincare products directly, but with theDear Reader,I am a Senior Derivatives Expert with over 10 years of experience in the field of Asset Management, specializing in equity analysis and research, macroeconomics, and risk-managed portfolio construction. My professional background covers both institutional and private client asset ...